Trending...
- Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
- Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
- Green Revolution CBD Spotlights Its Water-Soluble Focus Tincture With CBD, CBG and Lion's Mane
SEATTLE, May 13, 2024 ~ Seattle, WA- With the number of pediatric inflammatory bowel disease (IBD) diagnoses increasing globally, a clinical trial in Seattle is aiming to revolutionize treatment approaches through deep molecular profiling. The Seattle STRIDE study, a collaboration between Seattle Children's Research Institute and the Allen Institute for Immunology, has begun recruiting volunteers for its three-year study.
The trial plans to enroll 200 participants and utilize genomic tools to analyze tissue samples from routine tests. These single-cell analysis methods will provide a detailed understanding of how the immune system behaves in patients with IBD and how it responds to specific drug treatments over time.
According to Dr. Betty Zheng, an assistant professor of pediatrics at Seattle Children's and the principal investigator of the study, this deep immune profiling could offer an unprecedented view of the disease and potentially lead to new and improved treatments.
"IBD is a complex disease and we still have a limited understanding of its molecular mechanisms," said Dr. Zheng. "By partnering with the Allen Institute, we hope to gain a detailed view of these mechanisms in order to find better ways of treating our patients."
More on Washingtoner
The exact causes and progression of IBD, a chronic inflammatory condition affecting the digestive tract, have remained elusive. It is believed that a combination of genetic factors, immune dysregulation, and environmental or dietary factors may play a role.
In children, IBD can be more aggressive and difficult to treat compared to adults. Approximately 30% of pediatric IBD patients do not respond to initial treatments and nearly half will eventually become resistant to their current treatments. This can lead to serious consequences such as impaired growth, mental health issues, and missed educational and social activities.
Dr. Zheng believes that a deeper understanding of the molecular workings of the disease could lead to personalized treatment strategies instead of relying on one-size-fits-all approaches.
"Some children respond well to first-line therapies while others require multiple treatments or do not respond at all," she explained. "This is a major challenge in the clinic."
In addition to potentially improving treatment options, a deep dive into the molecular mechanisms of IBD could also uncover new pathways of inflammation that could be targeted for the development of new drugs.
More on Washingtoner
Dr. Adam Savage, an assistant investigator at the Allen Institute for Immunology, emphasized the importance of exploring these unknown pathways.
"There is a universe of information that is not being seen," he said.
To uncover this information, Dr. Savage and his team will utilize advanced technologies developed at the Allen Institute for Immunology to identify and pinpoint immune cells and molecules within tissue samples collected during routine hospital visits. By analyzing these samples over time, they hope to gain insight into how the disease progresses and how patients respond to treatment.
While the study may involve complex data and advanced technologies, Dr. Savage reminds us that the ultimate goal is to improve the lives of patients.
"We may look at data on computers or work in labs, but when we see the patients we are trying to help, it serves as a powerful reminder of why we do what we do - to have a real impact on patients' lives," he said.
Families interested in participating in the Seattle STRIDE study can find more information on their website. The study offers hope for improved treatments and better outcomes for children with IBD.
The trial plans to enroll 200 participants and utilize genomic tools to analyze tissue samples from routine tests. These single-cell analysis methods will provide a detailed understanding of how the immune system behaves in patients with IBD and how it responds to specific drug treatments over time.
According to Dr. Betty Zheng, an assistant professor of pediatrics at Seattle Children's and the principal investigator of the study, this deep immune profiling could offer an unprecedented view of the disease and potentially lead to new and improved treatments.
"IBD is a complex disease and we still have a limited understanding of its molecular mechanisms," said Dr. Zheng. "By partnering with the Allen Institute, we hope to gain a detailed view of these mechanisms in order to find better ways of treating our patients."
More on Washingtoner
- Scott Glickson Joins STS Capital Partners as Managing Director
- Spokane: City Closures Planned for the Thanksgiving Holiday
- BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
- Tacoma: Planning Commission to Hold Public Hearing on December 16 Regarding Proposed Tree and Landscape Code Update
- Enjoy the 2026 holidays with Spokane Parks & Recreation
The exact causes and progression of IBD, a chronic inflammatory condition affecting the digestive tract, have remained elusive. It is believed that a combination of genetic factors, immune dysregulation, and environmental or dietary factors may play a role.
In children, IBD can be more aggressive and difficult to treat compared to adults. Approximately 30% of pediatric IBD patients do not respond to initial treatments and nearly half will eventually become resistant to their current treatments. This can lead to serious consequences such as impaired growth, mental health issues, and missed educational and social activities.
Dr. Zheng believes that a deeper understanding of the molecular workings of the disease could lead to personalized treatment strategies instead of relying on one-size-fits-all approaches.
"Some children respond well to first-line therapies while others require multiple treatments or do not respond at all," she explained. "This is a major challenge in the clinic."
In addition to potentially improving treatment options, a deep dive into the molecular mechanisms of IBD could also uncover new pathways of inflammation that could be targeted for the development of new drugs.
More on Washingtoner
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth
- Auction Finder USA Surpasses 120,000 Live Auction Listings Across All 50 States
- PinnacleQM launches new enterprise website to help Australian organisations deliver more with confidence
- Tacoma: Statement from District 4 Council Member Sandesh Sadalge and At-Large Council Member Olgy Diaz on Sale of Northwest ICE Processing Center to Federal Government
- Loud! OOH Launches UK's First Free Planning Tool for UK Outdoor Advertising Budgets
Dr. Adam Savage, an assistant investigator at the Allen Institute for Immunology, emphasized the importance of exploring these unknown pathways.
"There is a universe of information that is not being seen," he said.
To uncover this information, Dr. Savage and his team will utilize advanced technologies developed at the Allen Institute for Immunology to identify and pinpoint immune cells and molecules within tissue samples collected during routine hospital visits. By analyzing these samples over time, they hope to gain insight into how the disease progresses and how patients respond to treatment.
While the study may involve complex data and advanced technologies, Dr. Savage reminds us that the ultimate goal is to improve the lives of patients.
"We may look at data on computers or work in labs, but when we see the patients we are trying to help, it serves as a powerful reminder of why we do what we do - to have a real impact on patients' lives," he said.
Families interested in participating in the Seattle STRIDE study can find more information on their website. The study offers hope for improved treatments and better outcomes for children with IBD.
0 Comments
Latest on Washingtoner
- Smith Strong Merges With Gravis Law, Bringing Gravis Law to Virginia
- Turkish Engineer Who Cracked Wall Street's Algorithm Launches Hermes AI Analyzer
- UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
- The Great Junk Hunt Returns to Puyallup: The Ultimate Holiday Vintage Market is Back!
- Green Revolution CBD Spotlights Its Water-Soluble Focus Tincture With CBD, CBG and Lion's Mane
- Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
- Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
- Coming Up on CNBC: Bilha Wachira Champions Financial Protection During Long-Term Care Awareness Month
- Tacoma: Closures Projected to Allow for Arterial Work
- Tacoma: Applicants Sought for the Bicycle Pedestrian Technical Advisory Group
- Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
- Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand
- Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
- Stamp Me Launches Web App Ahead of 15th Anniversary
- The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
- Spokane City Council Passes Chronic Nuisance Properties Ordinance
- City of Spokane and City Council Announce 2027 Legislative Priorities
- LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
- Security Planning Tips For Your Holiday Event From Access Patrol Services
- Tacoma: Council Member Sandesh Sadalge Focuses Today's District 4 Town Hall on the City's Biennial Budget